Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial

Abstract Introduction Non-alcoholic fatty liver disease (NAFLD) is one of the main causes of chronic liver disease worldwide. Flavonoids, a group of natural compounds, have garnered a great deal of attention in the management of NAFLD because of their profitable effects on glucose and lipid metaboli...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fatemeh Naeini, Zahra Namkhah, Helda Tutunchi, Seyed Mahdi Rezayat, Siavash Mansouri, Seyed Ali Jazayeri-Tehrani, Mehdi Yaseri, Mohammad Javad Hosseinzadeh-Attar
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Non-alcoholic-fatty liver disease Naringenin Metabolic parameters Adiponectin Neuregulin-4 Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/9ea2747d28804348b25ce7e45dc0a2e1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9ea2747d28804348b25ce7e45dc0a2e1
record_format	dspace
spelling	oai:doaj.org-article:9ea2747d28804348b25ce7e45dc0a2e12021-11-14T12:31:04ZEffects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial10.1186/s13063-021-05784-71745-6215https://doaj.org/article/9ea2747d28804348b25ce7e45dc0a2e12021-11-01T00:00:00Zhttps://doi.org/10.1186/s13063-021-05784-7https://doaj.org/toc/1745-6215Abstract Introduction Non-alcoholic fatty liver disease (NAFLD) is one of the main causes of chronic liver disease worldwide. Flavonoids, a group of natural compounds, have garnered a great deal of attention in the management of NAFLD because of their profitable effects on glucose and lipid metabolism, inflammation, and oxidative stress which are the pivotal pathophysiological pathways in NAFLD. Naringenin is a citrus-derived flavonoid with a broad spectrum of potential biological effects including anti-inflammatory and antioxidant properties, which may exert protective effects against NAFLD. The present clinical trial aims to examine the efficacy of naringenin supplementation on plasma adiponectin and neurogulin-4 (NRG-4) concentrations, metabolic parameters, and liver function indices in overweight/obese patients with NAFLD. Methods and analysis This is a double-blind, randomized, placebo-controlled clinical study that will investigate the impacts of naringenin supplementation in overweight/obese patients with NAFLD. Liver ultrasonography will be applied to diagnose NAFLD. Forty-four eligible overweight/obese subjects with NAFLD will be selected and randomly assigned to receive naringenin capsules or identical placebo (each capsule contains 100 mg of naringenin or cellulose), twice daily for 4 weeks. Participants will be asked to remain on their usual diet and physical activity. Safety of naringenin supplementation was confirmed by the study pharmacist. The primary outcome of this study is changes in adiponectin circulating levels. The secondary outcomes include changes in NRG-4 levels, liver function indices, metabolic parameters, body weight, body mass index (BMI), waist circumference (WC), blood pressure, and hematological parameters. Statistical analysis will be conducted using the SPSS software (version 25), and P value less than 0.05 will be regarded as statistically significant. Discussion We hypothesize that naringenin administration may be useful for treating NAFLD by modulating energy balance, glucose and lipid metabolism, oxidative stress, and inflammation through different mechanisms. The current trial will exhibit the effects of naringenin, whether negative or positive, on NAFLD status. Ethical aspects The current trial received approval from the Medical Ethics Committee of Tehran University of Medical Sciences, Tehran, Iran (IR.TUMS.MEDICNE.REC.1399.439). Trial registration Iranian Registry of Clinical Trials IRCT201311250155336N12 . Registered on 6 June 2020Fatemeh NaeiniZahra NamkhahHelda TutunchiSeyed Mahdi RezayatSiavash MansouriSeyed Ali Jazayeri-TehraniMehdi YaseriMohammad Javad Hosseinzadeh-AttarBMCarticleNon-alcoholic-fatty liver diseaseNaringeninMetabolic parametersAdiponectinNeuregulin-4Medicine (General)R5-920ENTrials, Vol 22, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Non-alcoholic-fatty liver disease Naringenin Metabolic parameters Adiponectin Neuregulin-4 Medicine (General) R5-920
spellingShingle	Non-alcoholic-fatty liver disease Naringenin Metabolic parameters Adiponectin Neuregulin-4 Medicine (General) R5-920 Fatemeh Naeini Zahra Namkhah Helda Tutunchi Seyed Mahdi Rezayat Siavash Mansouri Seyed Ali Jazayeri-Tehrani Mehdi Yaseri Mohammad Javad Hosseinzadeh-Attar Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
description	Abstract Introduction Non-alcoholic fatty liver disease (NAFLD) is one of the main causes of chronic liver disease worldwide. Flavonoids, a group of natural compounds, have garnered a great deal of attention in the management of NAFLD because of their profitable effects on glucose and lipid metabolism, inflammation, and oxidative stress which are the pivotal pathophysiological pathways in NAFLD. Naringenin is a citrus-derived flavonoid with a broad spectrum of potential biological effects including anti-inflammatory and antioxidant properties, which may exert protective effects against NAFLD. The present clinical trial aims to examine the efficacy of naringenin supplementation on plasma adiponectin and neurogulin-4 (NRG-4) concentrations, metabolic parameters, and liver function indices in overweight/obese patients with NAFLD. Methods and analysis This is a double-blind, randomized, placebo-controlled clinical study that will investigate the impacts of naringenin supplementation in overweight/obese patients with NAFLD. Liver ultrasonography will be applied to diagnose NAFLD. Forty-four eligible overweight/obese subjects with NAFLD will be selected and randomly assigned to receive naringenin capsules or identical placebo (each capsule contains 100 mg of naringenin or cellulose), twice daily for 4 weeks. Participants will be asked to remain on their usual diet and physical activity. Safety of naringenin supplementation was confirmed by the study pharmacist. The primary outcome of this study is changes in adiponectin circulating levels. The secondary outcomes include changes in NRG-4 levels, liver function indices, metabolic parameters, body weight, body mass index (BMI), waist circumference (WC), blood pressure, and hematological parameters. Statistical analysis will be conducted using the SPSS software (version 25), and P value less than 0.05 will be regarded as statistically significant. Discussion We hypothesize that naringenin administration may be useful for treating NAFLD by modulating energy balance, glucose and lipid metabolism, oxidative stress, and inflammation through different mechanisms. The current trial will exhibit the effects of naringenin, whether negative or positive, on NAFLD status. Ethical aspects The current trial received approval from the Medical Ethics Committee of Tehran University of Medical Sciences, Tehran, Iran (IR.TUMS.MEDICNE.REC.1399.439). Trial registration Iranian Registry of Clinical Trials IRCT201311250155336N12 . Registered on 6 June 2020
format	article
author	Fatemeh Naeini Zahra Namkhah Helda Tutunchi Seyed Mahdi Rezayat Siavash Mansouri Seyed Ali Jazayeri-Tehrani Mehdi Yaseri Mohammad Javad Hosseinzadeh-Attar
author_facet	Fatemeh Naeini Zahra Namkhah Helda Tutunchi Seyed Mahdi Rezayat Siavash Mansouri Seyed Ali Jazayeri-Tehrani Mehdi Yaseri Mohammad Javad Hosseinzadeh-Attar
author_sort	Fatemeh Naeini
title	Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
title_short	Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
title_full	Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
title_fullStr	Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
title_full_unstemmed	Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
title_sort	effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial
publisher	BMC
publishDate	2021
url	https://doaj.org/article/9ea2747d28804348b25ce7e45dc0a2e1
work_keys_str_mv	AT fatemehnaeini effectsofnaringeninsupplementationinoverweightobesepatientswithnonalcoholicfattyliverdiseasestudyprotocolforarandomizeddoubleblindclinicaltrial AT zahranamkhah effectsofnaringeninsupplementationinoverweightobesepatientswithnonalcoholicfattyliverdiseasestudyprotocolforarandomizeddoubleblindclinicaltrial AT heldatutunchi effectsofnaringeninsupplementationinoverweightobesepatientswithnonalcoholicfattyliverdiseasestudyprotocolforarandomizeddoubleblindclinicaltrial AT seyedmahdirezayat effectsofnaringeninsupplementationinoverweightobesepatientswithnonalcoholicfattyliverdiseasestudyprotocolforarandomizeddoubleblindclinicaltrial AT siavashmansouri effectsofnaringeninsupplementationinoverweightobesepatientswithnonalcoholicfattyliverdiseasestudyprotocolforarandomizeddoubleblindclinicaltrial AT seyedalijazayeritehrani effectsofnaringeninsupplementationinoverweightobesepatientswithnonalcoholicfattyliverdiseasestudyprotocolforarandomizeddoubleblindclinicaltrial AT mehdiyaseri effectsofnaringeninsupplementationinoverweightobesepatientswithnonalcoholicfattyliverdiseasestudyprotocolforarandomizeddoubleblindclinicaltrial AT mohammadjavadhosseinzadehattar effectsofnaringeninsupplementationinoverweightobesepatientswithnonalcoholicfattyliverdiseasestudyprotocolforarandomizeddoubleblindclinicaltrial
_version_	1718429182811176960

Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial

Ejemplares similares